These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19080742)

  • 1. Molecular profiling in glioblastoma: prelude to personalized treatment.
    Mladkova N; Chakravarti A
    Curr Oncol Rep; 2009 Jan; 11(1):53-61. PubMed ID: 19080742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
    Camara-Quintana JQ; Nitta RT; Li G
    Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
    Hegi ME; Stupp R
    Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme.
    El Hindy N; Keyvani K; Pagenstecher A; Dammann P; Sandalcioglu IE; Sure U; Zhu Y
    Neuro Oncol; 2013 Oct; 15(10):1366-78. PubMed ID: 23787764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
    Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
    J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.
    Schnell O; Albrecht V; Pfirrmann D; Eigenbrod S; Krebs B; Romagna A; Siller S; Giese A; Tonn JC; Schichor C
    Med Oncol; 2018 Jun; 35(7):103. PubMed ID: 29882028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT Promoter Mutations Correlate with IDHs, MGMT and EGFR in Glioblastoma Multiforme.
    Tomar MS; Shrivastava A
    Neurol India; 2021; 69(1):135-136. PubMed ID: 33642284
    [No Abstract]   [Full Text] [Related]  

  • 13. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
    Szopa W; Burley TA; Kramer-Marek G; Kaspera W
    Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
    Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
    Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
    J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E; Tosoni A; Pozzati E; Brandes AA
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.